Aducanumab, a new drug developed by Biogen for treatment of cognitive and functional decline in early Alzheimer’s disease, is scheduled for a clinical trial data review by a U.S. Food and Drug Administration (FDA) Advisory Committee on Nov. 6.

This is an exciting moment for millions of Americans and their loved ones who have waited decades for a new, more effective treatment for Alzheimer’s disease to be available.

Given the devastating toll of this disease and the publicly released research data, the Alzheimer’s Association has submitted a statement supporting approval to the FDA Advisory Committee, which will make its recommendation to the FDA.

Whatever the final decision by the FDA, this is an important moment. We have never before been this close to approval of a medication for Alzheimer’s that could change the progression of the disease, not just the symptoms. Together, we can continue working toward our vision of a world without Alzheimer’s and all other dementia.